Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Usage of Dapagliflozin - a Sodium Glucose Co-transporter Inhibitor, in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Egyptian Patients

NCT03624803 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03624803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03624803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Usage of Dapagliflozin - a Sodium Glucose Co-transporter Inhibitor, in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Egyptian Patients
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
March 9, 2019
Completion date
March 30, 2020
Enrollment
200 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

type-2 diabetes